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Electroconvulsive therapy (ECT) is the most effective treatment for a refractory major
depression in the context of both unipolar and bipolar affective disorders. However, the
relapse rate within the first 6 months after a successful course of ECT to treat a depres-
sive episode can be as high 50%. Evidence-based strategies to prevent relapse have partial
efficacy and are associated with problematic adverse effects limiting their use as long-
term treatments. Repetitive transcranial magnetic stimulation (rTMS) has demonstrated
efficacy in treatment-resistant depression with a favorable adverse effect profile. Herein,
we describe six patients, four with unipolar and two with bipolar depression, where rTMS
was used to maintain response after a successful course of acute and continuation ECT.
rTMS was administered once or twice weekly, at 120% of the resting motor threshold.
Patients received sequential bilateral rTMS (low frequency right: 600 pulses, then high
frequency left: 3000 pulses). The site of stimulation was 6 cm anterior and 1 cm lateral
from the site of maximum stimulation of the abductor pollicis brevis muscle. Depressive
symptoms were monitored with the quick inventory of depressive symptoms-self rated.
Five of the six patients were able to maintain their response status from 6 to 13 months
at the time of last observation. The use of rTMS may be an important relapse prevention
strategy following an acute course of ECT. Controlled studies comparing rTMS to current
evidence-based relapse prevention strategies are warranted.
Keywords: bilateral rTMS, ECT, relapse prevention, major depression, maintenance rTMS
BACKGROUND
Electroconvulsive therapy (ECT) is an established and important
treatment for severe or treatment-resistant depression (TRD) (1).
Despite the superior efficacy of ECT in TRD, relapse rates are
high after a successful course of treatment (2–4). With antide-
pressant monotherapy, patients can have a relapse rate as high
as 84% within 6 months after an acute course of ECT (2). Other
studies have shown that patients who receive pharmacotherapy in
a treatment as usual fashion following ECT relapse at a rate of
51% within 6 months of remission (3). High relapse rates after an
acute course of ECT is a major problem for the field of convulsive
therapy (4–6).
The best evidence for preventing relapse in depression after an
acute course of ECT consists of continuation pharmacotherapy
(C-Pharm) or continuation electroconvulsive therapy (C-ECT)
(7, 8). A Consortium for Research in ECT (CORE) study found
that both C-Pharm and C-ECT are superior to a placebo con-
trol in reducing the rate of relapse, however both groups still
had relatively high relapse rates of 31.6 and 37.1% over 6 months,
respectively (7). The relapse rates at 6 months after an acute ECT
course did not differ statistically between the two groups (7). In this
regard, C-ECT and C-Pharm are the two evidence-based strategies
for preventing relapse after an acute ECT course (9). For C-Pharm
the seminal studies used the combination of nortriptyline and
lithium (2, 7). The tolerability and narrow therapeutic index of
lithium can limit the acceptance of the treatment by patients (10).
Furthermore, a recent study demonstrated that both nortriptyline
and venlafaxine combined with lithium only reduced the relapse
rate to 50% within the first 6 months after remission with ECT
(11). C-ECT necessitates ongoing ECT that although at a reduced
frequency over 6 months that can delay and prolong recovery from
the cognitive adverse effects of the acute ECT course (12). Thus,
other treatments that can effectively maintain response with fewer
adverse effects are greatly needed.
Repetitive transcranial magnetic stimulation (rTMS) has
emerged as a new treatment for TRD (13). Unlike ECT, rTMS
does not require anesthesia. rTMS is a non-invasive and well-
tolerated treatment for depression that has a favorable adverse
effect profile (14). Meta-analyses have reported that the effect
size of rTMS treatment for depression is around 0.55 (15, 16)
which is comparable to at least a subset of antidepressant med-
ications that have effect sizes in the range of 0.17–0.46 (17, 18).
The antidepressant effect of rTMS appears to be as durable as
with other antidepressant treatments (19). Early studies suggested
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that rTMS had almost equivalent antidepressant effect as ECT in
non-psychotic major depression (20) with similar long-term out-
comes at 3 and 6 months (21). However, the accumulation of data
has demonstrated that rTMS does not have as robust efficacy as
ECT (16, 22, 23).
Though its efficacy may not be as robust as ECT, rTMS may have
a similar mechanisms of action (24, 25), as it induces a micro-
electrical current in the underlying cortical tissue and results in
localized neuronal depolarization (26, 27). rTMS has the signifi-
cant advantage of being able to electrically stimulate cortical tissue
without the need for sedation. In addition, rTMS has a supe-
rior tolerability profile and does not adversely effect cognition
(13). Though there are relatively few studies that have examined
maintenance of response after an acute course of rTMS, emerging
data suggests that a schedule of clustered treatments can main-
tain response in those that have responded to an acute course of
rTMS (28).
Herein we describe the use of rTMS to maintain response in
six patients who initially responded to an acute and continuation
course of ECT and requested to discontinue the course of ECT
due to poor tolerability or cognitive side effects.
CASE SERIES
SUBJECTS, CLINICAL MEASURE, AND MEDICATION
Six patients with TRD were switched to twice or once weekly rTMS
after ECT treatment. All the patients had recurrent episodes and
had failed at least two antidepressant medications in the current
episode. Table 1 shows a descriptive data on the demographic,
clinical characteristics of the six subjects. Patients were switched
from ECT to rTMS treatment for clinical reasons including: (i)
patients did not wish to continue with ECT due to concerns
around side effects and the overall tolerability of the procedure,
or (ii) patients complained of significant cognitive impairment,
or (iii) patients declined the addition of lithium to their anti-
depressant treatment. Depressive symptoms were assessed using
the Quick Inventory of Depressive Symptoms-Self Rated (QIDS-
SR) (29) with weekly administration throughout both ECT and
rTMS treatment courses. The definition of symptom severity of
using the QIDS-SR was: normal (0–5), mild (6–10), moderate
(11–15), severe (16–20), and very severe (over 21). Remission was
defined by QIDS-SR score less than 6. Response was defined as
a 50% improvement from baseline and “partial response” was
defined as 25% improvement from baseline. Four women and two
men between the ages of 27 and 58 (mean± S.D= 48± 11) are
described in this series. Four had a diagnosis of unipolar depres-
sion and the remaining two bipolar depression, with refractory
type of depression. They were prescribed one or two antidepres-
sant medications during ECT and rTMS treatments. The average
Imipramine-equivalent dose of the antidepressant medications
during the maintenance rTMS period was 294± 161 mg/day in
these patients (30). Medications were kept constant during the
rTMS treatment course with minor dosage adjustments and no
absolute changes to antidepressant or augmentation agents.
ECT COURSE
Electroconvulsive therapy was administered using the seizure titra-
tion method using a MECTA Spectrum 5000Q. All patients started
Table 1 | Clinical and demographic characteristics.
CHARACTERISTICS
Number of patients 6
Age 48±11 (mean±S.D)
Gender (male/female) 2/4
Diagnosis: bipolar depression 2
Unipolar depression 4
Antidepressant medications**
(imipramine-equivalent dose)
294±161 (mg/day)
Number of acute ECT 14±5
Number of continuation ECT 15±9
Number of maintenance rTMS 54±11
Baseline score of QIDS-SR (start of ECT) 17±3
Midterm score of QIDS-SR (start of rTMS) 8±6
Ongoing score of QIDS-SR (last rTMS) 8±4
**During the maintenance rTMS period.
with right unilateral ultra-brief (RUL-UB) pulse width (0.3 ms)
ECT with seizure threshold titration. Subsequent treatment was
administered at six times the seizure threshold. This technique has
been shown to be an effective treatment with a reduced cogni-
tive side effect profile (31). Two patients were switched to bilateral
standard pulse width ECT due to lack of response to RUL-UB and
seizure threshold was re-titrated. Bilateral ECT was administered
using a pulse width of 1.0 ms at 1.5 times the seizure threshold.
The length of acute ECT courses ranged from 9 to 20 treatments
twice or three times weekly. The average acute course length was
14± 5 (mean± S.D) treatments. All but one went onto a course
of C-ECT course that ranged from 8 to 31 treatments prior to
switching to rTMS. The average length was 15± 9 (mean± S.D)
continuation ECT treatments.
rTMS COURSE
Repetitive transcranial magnetic stimulation was administered
using a MagPro RX100 Repetitive Magnetic Stimulator (Magven-
ture, Denmark) and a hand-held B65, figure-of-8 coil. rTMS was
administered once or twice weekly, at an intensity of 120% of
the resting motor threshold. The intensity was administered at
as a percentage of the maximum stimulator output (MSO). For
example, if the resting motor threshold was 40% MSO the inten-
sity of treatment would be delivered at 48% MSO. Choice of one
or two treatments per week was based on the severity of depres-
sion and patient’s compliance to the treatment. Patients received
sequential bilateral rTMS using low frequency right (LFR) for 600
pulses in one continuous train, then high frequency left (HFL)
for 3000 pulses. For the HFL stimulation the number of pulses
per train was 50, for 60 trains with an inter-train interval of 20 s.
The site of stimulation was 6 cm anterior and 1 cm lateral from
the site of maximum stimulation of the abductor pollicis brevis
muscle. This location has been advocated as more accurately tar-
geting the dorsolateral prefrontal cortex (DLPFC) (32, 33). The
rTMS protocol was based on studies showing demonstrating effi-
cacy with sequential bilateral rTMS (34, 35). The frequency was
chosen based on clinical experience in our center with mainte-
nance rTMS. One patient was switched from sequential bilateral
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rTMS to an extended, 6000 pulse, session of HFL rTMS alone (120
trains of 50 pulses with an inter-train interval of 20 s). The length
of the maintenance rTMS course, at last observation, ranged from
44 to 66 treatments (mean± S.D= 54± 11) which translates to a
mean of 9 months. Patients were offered rTMS on compassionate
grounds based on their history of difficult to treat depression. Prior
to consenting to rTMS, patients were informed of the rationale for
using rTMS to maintain response and the limitation that using
rTMS in this context had not been investigated in randomized
controlled studies.
CASE 1
Case 1 is a 27-year-old woman with a major depressive episode
in the context of bipolar disorder (BD) type I. The depressive
episode was of moderate to severe severity without psychotic
symptoms. She had failed several antidepressant and mood stabi-
lizers including lithium during the current depressive episode. She
had an acute course of nine RUL-UB pulse width treatments over
1 month and eight continuation RUL-UB pulse width treatments
over 3 months. During ECT treatment, she was not prescribed any
psychotropic medications. She had a greater than 50% reduction
in QIDS scores at the end of her ECT course (23 to 10). She wished
to stop the C-ECT course due to concerns over the disruption in
her daily schedule and cognitive adverse effects. She began a course
of rTMS within 1 week of her last ECT treatment and had a total 40
sessions over 6 months twice per week, that consisted of 600 pulses
of LFR prefrontal rTMS at 41% of the MSO and 3000 pulses of
HFL prefrontal rTMS at 43% MSO. During rTMS treatment she
was prescribed trazodone for sleep, PRN lorazepam for anxiety,
and zopiclone PRN. When she began rTMS (i.e., at the end of
ECT) her QIDS-SR score was 13 and dropped to 10 at the end of
her rTMS course (at several time points during the rTMS course
her QIDS-SR score was in the remission range).
CASE 2
Case 2 is a 47-year-old woman with a major depressive episode in
the context of BD type II. The depressive episode was of moderate
severity and she had failed two adequate trials of an antidepres-
sants with augmentation. She had an acute course of 18 RUL-UB
pulse width treatments over 2 months and 31 continuation and
maintenance RUL-UB pulse width treatments over 9 months. Dur-
ing ECT treatment, she was prescribed venlafaxine, nortriptyline,
olanzapine, aripiprazole, lithium, and zopiclone. The venlafaxine
and olanzapine were discontinued during the acute ECT course
and the nortriptyline dose was optimized. She had a greater than
50% reduction in QIDS-SR scores at the end of her ECT course (13
to 3). At the end of the acute ECT course her QIDS-SR score were
in the remission range. She began to notice cognitive impairments
during the maintenance ECT course and wished to discontinue
the treatment. Due to her history of recurrent episodes rTMS was
considered. She received a total 58 sessions on a once weekly basis
over 13 months that consisted of 600 pulses of LFR rTMS at 54%
MSO and 3000 pulses of HFL rTMS at 46% MSO. During rTMS
treatment, nortriptyline, lithium, aripiprazole, and zopiclone were
prescribed with no dose changes. When she began rTMS (after
stopping her maintenance ECT course) her QIDS-SR score was 2
and was maintained at 3 at the last observation.
CASE 3
Case 3 is a 58-year-old woman with a depressive episode in the
context of a major depressive disorder (MDD). The depressive
episode was of moderate severity. She had failed two antidepres-
sant of adequate dose and duration. She had an acute course of
10 RUL-UB pulse width treatments. During ECT treatment she
was prescribed fluoxetine. Despite achieving remission (QIDS-SR
score of 3) with her acute course of ECT she did not like the anes-
thetic side effects and declined a course of C-ECT, she also declined
the addition of lithium due to concern over side effects. Given her
history of recurrent episodes a course of rTMS was offered. She
received 66 sessions of rTMS twice weekly over 11 months. She
received 600 pulses of LFR rTMS at 43% MSO and 3000 pulses of
HFL rTMS at 52% MSO. During rTMS treatment, fluoxetine was
continued. Her QIDS score was 2 at the last observation.
CASE 4
Case 4 is a 51-year-old man with a major depressive episode in
the context of MDD. The depressive episode was of severe sever-
ity and failed to respond to at least two antidepressants trials of
adequate dose and duration. He had an acute course of six RUL-
UB pulse width treatments, but due to lack of response he was
then switched to bitemporal ECT for another 14 treatments. Dur-
ing ECT treatment, he was prescribed mirtazapine, paroxetine,
clonazepam, gabapentin, and zopiclone. The gabapentin and clon-
azepam were discontinued during the ECT course. He had a partial
response to ECT and the severity of depression was reduced to the
moderate range (QIDS-SR went from 18 to 13). Due to cognitive
adverse effects he was offered a course of rTMS. As the patient
lived a far distance from the hospital he was only able to attend on
a once weekly basis. He received 52 rTMS treatments once weekly
over 7 months that consisted of 600 pulses of LFR rTMS at 57%
MSO and 3000 pulses of HFL rTMS at 57% MSO. During rTMS
treatment, he took mirtazapine, paroxetine, and zopiclone. When
he began rTMS (i.e., at the end of ECT) his QIDS score was 13
and dropped to 12 at the last observation, during periods of his
rTMS course his QIDS score was as low as 7. Subjectively, the
patient reported significant improvement in his symptoms during
the rTMS course.
CASE 5
Case 5 is a 51-year-old man with a major depressive episode in
the context of MDD. The depressive episode was of severe severity
and he failed two antidepressants of adequate dose and duration.
He received an acute course of 11 RUL-UB pulse width treatments
and 15 continuation and maintenance RUL-UB pulse width treat-
ments over 7 months. During ECT treatment, he was prescribed
venlafaxine and nortriptyline. He had a partial response to the
acute ECT course and the severity of the depression was reduced
to the moderate range (QIDS score of 11). Due to cognitive adverse
effects he was offered a course of rTMS. He received a total 65 rTMS
treatments, twice per week, over 10 months that consisted of 600
pulses of LFR rTMS at 54% MSO and 3000 pulses of HFL rTMS
at 57% MSO twice a week for 5 months. Due to ongoing partial
response (QIDS score of 12) he was switched to 6000 pulses of
HFL rTMS at 56% twice a week over the next 5 months. At peri-
ods during the 6000 pulse HFL rTMS course his QIDS score was as
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low as 8. At the last observation period his QIDS score remained in
the moderate range at 11. The reduction of his depression scores
into the moderate range was greater than the improvement he had
with medication and led to the continuation of rTMS despite the
partial response.
CASE 6
Case 6 is a 56-year-old woman with a major depressive episode
in the context of MDD. The depressive episode was severe with
psychotic features. She had an acute course of 13 RUL-UB pulse
width treatments and 10 continuation RUL-UB pulse width treat-
ments over 2 months. At the beginning of her ECT treatment,
she was prescribed mirtazapine, desvenlafaxine, risperidone, and
clonazepam. The venlafaxine was switched to nortriptyline and
the clonazepam was discontinued during the ECT course. She
had a good response to the acute course of ECT and her QIDS-
SR score were in the remission range. Despite achieving remis-
sion (QIDS-SR score of 2) with ECT she had difficulty toler-
ating the side effects of the anesthesia, the disruption in her
daily life, and wished to discontinue the C-ECT. Due to her
history of a severe episode with psychotic features and her his-
tory of recurrent episode she was offered a course of rTMS.
She received a total of 44 rTMS treatments, twice per week,
over 6 months that consisted of 600 pulses of LFR rTMS at
82% MSO and 3000 pulses of HFL rTMS at 72% MSO. During
rTMS treatment, she was prescribed mirtazapine, nortriptyline,
and risperidone. At the last observation her QIDS-SR score was a
9. Despite experiencing a mild worsening in her depressive symp-
toms she continued to be significantly improved from her index
episode.
SUMMARY
Figure 1 shows the changes in QIDS-SR score throughout the
treatment courses in each subject. The mean score of 8 (mild
depression) was maintained through the rTMS treatment. The
mean score decreased from severe to mild and was maintained in
this range throughout the course of treatment. Individually, each
patient achieved a significant decrease in their QIDS-SR score
between the acute ECT and the rTMS courses. This decrease in
QIDS-SR score translates to a change in symptom severity cat-
egory. Two patients decreased by three severity categories, two
decreased by two categories, and two decreased by one category.
Five of the six patients maintained the response level that they
had achieved during their acute and C-ECT courses. One patient
(Case 6) had an increase in QIDS score from remission to the
mild depression range during the rTMS treatment course. This
increase in symptom level was not considered a relapse for the
patient. The duration of response or partial response ranged from
6 to 13 months at the time of last observation. All patients tol-
erated the rTMS very well without any serious adverse effects.
Two patients reported mild headache and scalp discomfort dur-
ing the first several treatments but these side effects subsided
quickly.
DISCUSSION
In this case series we present data for the effectiveness of
rTMS to maintain response after achieving remission and/or
FIGURE 1 | Longitudinal changes in QIDS score of each subject over
acute ECT course and maintenance rTMS treatment for refractory
depression.
response following a course of ECT in refractory depression.
There is relatively little data that has investigated maintenance
rTMS treatment to prevent relapse in TRD patients who have
responded well to an acute course of ECT (36). This case series
is in keeping with another recent case series (37). In that case
series, the authors found that rTMS primarily administered as
HFL, at a ratio of two rTMS to one ECT session, was effec-
tive at maintaining response in four of the six patients. Two
of the six patients were switched to sequential bilateral rTMS
and total pulses were increased to 6600 pulses in another two
cases. Taken together, the current case series and the series pre-
sented by Cristancho et al. suggest that rTMS delivered more
frequently than C-ECT may be a promising strategy to maintain
response in patients who cannot tolerate or decline C-ECT and/or
maintenance ECT.
The maintenance of response or partial response from the end
of the ECT course ranged from 6 to 13 months at the last obser-
vation period during the rTMS course. Only one patient had a
partial worsening of symptoms. The maintenance of the response
for the patients in this case series was clinically significant in the
context of the chronicity of their illnesses.
These results suggest that once ECT is effective for TRD, rTMS
preferably at a frequency of twice per week can maintain the
response achieved by ECT. All patients tolerated the treatment
well. The rTMS delivered in this series was felt to be less invasive
and more tolerable to the patients. The alternative evidence-
based options to maintain response within the first 6 months after
response from an acute ECT course can pose tolerability issues and
patients often decline the two options. The adverse effect profile
and tolerability of rTMS may be more appealing to patients. How-
ever, the twice weekly treatment schedule may be overly onerous
to some.
There are several limitations to this case series. First, clinician-
rated measures of clinical symptom severity were not collected.
There are limitations to self-report measures that are not corrob-
orated by a clinician-rated measure (38, 39). Second, longitudi-
nal changes in cognitive function in the patients after remission
with ECT course were not evaluated. As the cause for discon-
tinuing ECT in several cases was cognitive adverse effects an
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assessment of cognitive function and recovery during the rTMS
course would be an important measure to include in a prospec-
tive study. Third, rTMS was started after patients had already
had some C-ECT; it is possible that the maintenance of response,
during rTMS was affected by the previous C-ECT course. In addi-
tion, we were not able to control for the confounding effects
of medication, because the type and dose of medications were
not constant in these patients. However, there were no medica-
tion switches during the rTMS course. Finally, the case series
is limited by its retrospective nature and the lack of a control
group.
These limitations notwithstanding, this case series suggests
that maintenance rTMS may be another potential treatment
to maintain response after a successful course of ECT. Con-
trolled studies comparing rTMS to current evidenced-based
relapse prevention strategies such as C-ECT or C-Pharm are war-
ranted. Such studies should include comprehensive measures of
cognition.
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